Sources in this nutrition section
Cui et al. Chinese Medicine (2025) 20:82 Page 65 of 91
WEE1 WEE1 G2 checkpoint kinases
Acknowledgements: We would like to thank Prof. WANG Yitao, Prof. CHEN Xiuping, Prof. LU Jinjian, and all our colleagues for their sincere and generous help.
Author contributions
ZZ, WT, and YF designed, organized, and supervised this word. DC, CZ, LZ,
JZ, JW, LH, HJ, QK, YZ, NL, ZS, WZ, JW, SZ drafted the manuscript. DC, CZ, WT,
and ZZ revised the manuscript. All authors read and approved of the fnal
manuscript.
Funding
The work was supported by grants from the Science and Technology
Development Fund, Macau SAR, China (No. 0123/2022/A, 0008/2023/RIC,
001/2023/ALC, 0006/2020/AKP, and 005/2023/SKL), the Outstanding Youth
of the Fundamental Research Funds for the Central Universities (lzujbky-
2021-ey21), the Shenzhen-Hong Kong-Macau S&T Program (Category C) (SGDX2020110309420200), the Research Fund of University of Macau (MYRG-GRG2023-00198-ICMS and SRG2022-00052-ICMS), the Research Grants Committee Fund, Hong Kong (Project Codes: 17152116 and 17121419), the Health and Medical Research Fund, Hong Kong (Project code: 18192141 and 21222101), and the Innovation and Technology Fund, Hong Kong (PRP/069/22FX).
Availability of data and materials
The manuscript is approved by all authors for publication.
Competing interests: The authors declare no competing interests.
Received: 30 December 2024 Accepted: 5 May 2025References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLO-
BOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries. Cancer J Clin. 2024;74(3):229–63.
2. Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics. Cancer J Clin.
2025;75(1):10–45.
3. Liao P, Yan B, Wang C, et al. Telomeres: dysfunction, maintenance, aging and cancer. Aging Dis. 2024;15(6):2595–631.
4. Kordowitzki P, Graczyk S, Mechsner S, et al. Shedding Light on the interaction Between Rif1 and telomeres in ovarian cancer. Aging Dis.
2024;15(2):535–45.
5. Cancer Genome Atlas Research N. The molecular taxonomy of primary
prostate cancer. Cell. 2015;163(4):1011–25.
6. Megerian MF, Kim JS, Badreddine J, et al. Melatonin and prostate
cancer: anti-tumor roles and therapeutic application. Aging Dis.
2023;14(3):840–57.
7. Holder AM, Dedeilia A, Sierra-Davidson K, et al. Defning clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498–512.
8. Rani L, Thapa K, Kanojia N, et al. An extensive review on the conse-
quences of chemical pesticides on human health and environment. J
Clean Prod. 2021;283: 124657.
9. Tang X, Yang T, Yu D, et al. Current insights and future perspectives of
ultraviolet radiation (UV) exposure: Friends and foes to the skin and
beyond the skin. Environ Int. 2024;185: 108535.
10. Pfeferkorn RM, Mortzfeld BM, Fink C, et al. Recurrent phases of strict
protein limitation inhibit tumor growth and restore lifespan in a dros-
ophila intestinal cancer model. Aging Dis. 2024;15(1):226–44.
11. Ruiz E, Kandil E, Alhassan S, et al. An integrative multi-omics analysis
of the molecular links between aging and aggressiveness in thyroid
cancers. Aging Dis. 2023;14(3):992–1012.
12. Zhong ZF, Vong CT, Chen FY, et al. Immunomodulatory potential of
natural products from herbal medicines as immune checkpoints inhibitors: Helping to fght against cancer via multiple targets. Med Res Rev. 2022;42(3):1246–79.
13. Huang J, Shi R, Chen F, et al. Exploring the anti-hepatocellular carci-
noma efects of Xianglian pill: Integrating network pharmacology
and RNA sequencing via in silico and in vitro studies. Phytomedicine.
2024;133: 155905.
14. Luo H, Vong CT, Chen H, et al. Naturally occurring anti-cancer
compounds: shining from Chinese herbal medicine. Chin Med. 2019.
https://doi.org/10.1186/s13020-019-0270-9.
15. Tan W, Lu J, Huang M, et al. Anti-cancer natural products isolated from
Chinese medicinal herbs. Chin Med. 2011;6:27.
16. Zhou FF, Aipire A, Xia LJ, et al. Marchantia polymorpha L. ethanol extract induces apoptosis in hepatocellular carcinoma cells via intrinsic- and endoplasmic reticulum stress-associated pathways. Chin Med. 2021.
https://doi.org/10.1186/1749-8546-6-27.
17. Yuan RYK, Fan QM, Liang XW, et al. Cucurbitacin B inhibits TGF-β1-
induced epithelial-mesenchymal transition (EMT) in NSCLC through
regulating ROS and PI3K/Akt/mTOR pathways. Chin Med. 2022;17(1):1.
18. Dou XJ, Zhou ZQ, Ren RM, et al. Apigenin, favonoid component
isolated from Gentiana veitchiorum fower suppresses the oxidative
stress through LDLR-LCAT signaling pathway. Biomed Pharmacother.
2020;128:40.
19. Alghamdi A, Almuqbil M, Alrofaidi MA, et al. Potential antioxidant activ-
ity of apigenin in the obviating stress-mediated depressive symptoms
of experimental mice. Molecules. 2022;27(24):5.
20. Sherif SG, Tarek M, Sabry YG, et al. Efect of apigenin on dynamin-related
protein 1 in type 1 diabetic rats with cardiovascular complications.
Gene. 2024;898:14.
21. Hong S, Dia VP, Zhong QX. Synergistic anti-infammatory activity of
apigenin and curcumin co-encapsulated in caseins assessed with
lipopolysaccharide-stimulated RAW 264.7 macrophages. Int J Biol
Macromol. 2021;193:702–12.
22. Jiang Z-B, Wang W-J, Xu C, et al. Luteolin and its derivative apigenin
suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett. 2021;515:36–48.
23. Adel M, Zahmatkeshan M, Akbarzadeh A, et al. Chemotherapeutic
efects of Apigenin in breast cancer: Preclinical evidence and molecular
mechanisms; enhanced bioavailability by nanoparticles. Biotechnol. Rep. 2022;34: e00730.
24. Tong J, Shen Y, Zhang Z, et al. Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway. Biosci Rep. 2019;39(5):16.
25. Woo J-S, Choo G-S, Yoo E-S, et al. Apigenin induces apoptosis by regu-
lating Akt and MAPK pathways in human melanoma cell A375SM. Mol
Med Rep. 2020;22(6):4877–89.
26. Chien M-H, Lin Y-W, Wen Y-C, et al. Targeting the SPOCK1-snail/slug
axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. J Exp Clin Cancer
Res. 2019;38:1–17.
27. Bao Y, Wu X, Jin X, et al. Apigenin inhibits renal cell carcinoma cell prolif-
eration through G2/M phase cell cycle arrest. Oncol Res. 2022;47(3):1–7.
28. Chen Y-H, Wu J-X, Yang S-F, et al. Anticancer efects and molecu-
lar mechanisms of apigenin in cervical cancer cells. Cancers. 2022;14(7):1824.
29. Heydarzadeh S, Moshtaghie AA, Daneshpour M, et al. The efect of
Apigenin on glycometabolism and cell death in an anaplastic thyroid
cancer cell line. Toxicol Appl Pharmacol. 2023;475: 116626.
30. Ruela-de-Sousa R, Fuhler GM, Blom N, et al. Cytotoxicity of apigenin on
leukemia cell lines: implications for prevention and therapy. Cell Death
Dis. 2010;1(1):e19–e19.
31. Huang J, Chen X, Chang Z, et al. Boosting anti-tumour immunity using
adjuvant Apigenin. Anticancer Agents Med Chem. 2023;23(3):266–77.
32. Li Q, Li L, Zhao X, et al. Apigenin induces apoptosis and reverses
the drug resistance of ovarian cancer cells. Int J Clin Exp Med.
2020;13(3):1987–94.